Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.82 |
| ▸ | F10 | P00742 | 16/20 | 0.66 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10178247 | 0.91 | KCNH2 (0.71) | KCNH2F10F2KLKB1 | |
| SCHEMBL10181300 | 0.90 | KCNH2 (1.00) | KCNH2F10F2 | |
| SCHEMBL10178716 | 0.89 | F10 (0.79) | KCNH2F10F2KLKB1 | |
| SCHEMBL890937 | 0.87 | KCNH2 (0.75) | KCNH2F10F2KLKB1 | |
| SCHEMBL10180837 | 0.87 | KCNH2 (0.75) | KCNH2F10F2 | |
| SCHEMBL10181315 | 0.87 | KCNH2 (0.75) | KCNH2F10F2 | |
| SCHEMBL10179140 | 0.86 | KCNH2 (0.74) | KCNH2F10F2 | |
| SCHEMBL890921 | 0.86 | F10 (0.79) | KCNH2F10F2KLKB1 | |
| SCHEMBL12134302 | 0.85 | KCNH2 (0.82) | KCNH2F10F2 | |
| SCHEMBL10181688 | 0.83 | KCNH2 (0.84) | KCNH2F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-9629831-B2 | Benzamides and related inhibitors of factor XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9108922-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8691847-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8063036-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7727982-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727982-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727981-B2 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131411-A1 | monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders | F12, F2, PIGS | KCNH2 2996/4885F10 19/4885F2 2/4885 |
| US-20160317511-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20100298284-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20140377247-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20120083602-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20130172310-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | KCNH2 1101/4885F10 18/4885F2 1/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | KCNH2 1032/4885F10 13/4885F2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.